- Home
- ALGS vs ATNM Comparison
ALGS vs ATNM Comparison
Compare ALGS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | ATNM |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 37.1M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALGS | ATNM |
|---|---|---|
| Price | $5.58 | $1.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $52.38 | $3.60 |
| AVG Volume (30 Days) | 39.1K | ★ 133.6K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $2,186,000.00 | $90,000.00 |
| Revenue This Year | $1,562.10 | $19,344.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.59 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.98 | $0.74 |
| 52 Week High | $13.69 | $1.74 |
Technical Indicators
Market Signals| Indicator | ALGS | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 46.48 |
| Support Level | $4.81 | $0.98 |
| Resistance Level | $6.12 | $1.13 |
| Average True Range (ATR) | 0.38 | 0.06 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 58.78 | 3.14 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.